• SES AI Corporation (NYSE:SES) faces significant challenges with a Return on Invested Capital (ROIC) of -35.23% and a Weighted Average Cost of Capital (WACC) of 5.30%, indicating inefficiencies in capital utilization.
• Comparatively, Yield10 Bioscience, Inc. showcases strong growth potential with a ROIC of 243.83% and a WACC of 4.64%, demonstrating efficient capital management.

SES AI Corporation (NYSE:SES) is a company involved in the development and commercialization of advanced battery technologies. The company focuses on creating high-performance lithium-metal batteries, which are crucial for electric vehicles and other energy storage applications. In the competitive landscape, SES faces peers like Solid Power, Inc. and Yield10 Bioscience, Inc., each with varying degrees of capital efficiency.

SES AI Corporation's financial metrics reveal a challenging situation. With a Return on Invested Capital (ROIC) of -35.23% and a Weighted Average Cost of Capital (WACC) of 5.30%, SES is not generating returns above its cost of capital. This negative ROIC indicates inefficiencies in how SES utilizes its capital, which could impact its long-term financial health.

In comparison, BIMI International Medical Inc. shows an even more concerning ROIC of -118.77% against a WACC of 62.74%. This results in a ROIC to WACC ratio of -1.89, highlighting severe inefficiencies. Similarly, Viveve Medical, Inc. has a ROIC of -100.93% and a WACC of 18.60%, leading to a ratio of -5.43, indicating poor capital utilization.

On the other hand, Yield10 Bioscience, Inc. stands out with a ROIC of 243.83% and a WACC of 4.64%, resulting in a ROIC to WACC ratio of 52.55. This suggests that Yield10 is effectively utilizing its capital to generate returns far exceeding its cost, showcasing strong growth potential and efficient capital management.